Fresenius SE & Co KGaA
XETRA:FRE

Watchlist Manager
Fresenius SE & Co KGaA Logo
Fresenius SE & Co KGaA
XETRA:FRE
Watchlist
Price: 33.48 EUR 0.09% Market Closed
Market Cap: 18.9B EUR
Have any thoughts about
Fresenius SE & Co KGaA?
Write Note

Fresenius SE & Co KGaA
Change in Working Capital

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Fresenius SE & Co KGaA
Change in Working Capital Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Change in Working Capital CAGR 3Y CAGR 5Y CAGR 10Y
Fresenius SE & Co KGaA
XETRA:FRE
Change in Working Capital
€737m
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
F
Fresenius Medical Care AG & Co KGaA
XETRA:FME
Change in Working Capital
-€589.6m
CAGR 3-Years
7%
CAGR 5-Years
-3%
CAGR 10-Years
-17%
Vita 34 AG
XETRA:V3V
Change in Working Capital
€3.3m
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
E
Euroeyes International Eye Clinic Ltd
HKEX:1846
Change in Working Capital
-HK$70.9m
CAGR 3-Years
12%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Synlab AG
XETRA:SYAB
Change in Working Capital
-€68.9m
CAGR 3-Years
28%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Fresenius Medical Care AG
XMUN:FME
Change in Working Capital
-€589.6m
CAGR 3-Years
7%
CAGR 5-Years
-3%
CAGR 10-Years
-17%
No Stocks Found

Fresenius SE & Co KGaA
Glance View

Market Cap
18.9B EUR
Industry
Health Care

Fresenius SE & Co. KGaA, a titan in the global healthcare sector, traces its origins to a humble pharmacy in Frankfurt, Germany, in 1912. Since then, the company has evolved into a multifaceted healthcare conglomerate, positioning itself prominently in four main divisions: Fresenius Medical Care, Fresenius Kabi, Fresenius Helios, and Fresenius Vamed. Each segment synergizes to form a comprehensive healthcare ecosystem. Fresenius Medical Care, the crown jewel of the group, stands as the world’s leading provider of products and services for individuals with renal diseases. This division, with a focus on dialyzing patients suffering from chronic kidney failure, operates a vast network of dialysis clinics and manufactures dialysis machines and related products that account for a significant portion of its income. Meanwhile, Fresenius Kabi, the pharmaceutical and medical device division, specializes in lifesaving drugs and technologies for critically and chronically ill patients. This division thrives on providing clinical nutrition, infusion therapy, and generics, positioning itself as a critical player in hospitals worldwide. Fresenius Helios is acknowledged as Europe's largest private hospital operator, managing a vast array of healthcare facilities that deliver inpatient and outpatient care, ensuring a steady stream of revenue through diverse healthcare services. Lastly, Fresenius Vamed provides a wide range of services for healthcare facilities, from project development and construction to full operational management, allowing the company to gain financial benefits from turnkey hospital solutions and infrastructure development. Through these concerted efforts, Fresenius SE & Co. KGaA cements its role as a key stakeholder in the global healthcare market, generating substantial revenues while addressing diverse medical needs across the globe.

FRE Intrinsic Value
73.78 EUR
Undervaluation 55%
Intrinsic Value
Price

See Also

What is Fresenius SE & Co KGaA's Change in Working Capital?
Change in Working Capital
737m EUR

Based on the financial report for Sep 30, 2024, Fresenius SE & Co KGaA's Change in Working Capital amounts to 737m EUR.

What is Fresenius SE & Co KGaA's Change in Working Capital growth rate?
Change in Working Capital CAGR 1Y
243%

Over the last year, the Change in Working Capital growth was 243%.

Back to Top